Park Medi IPO vs Nephrocare Health IPO: Full Comparison of GMP, Price Band, Listing & Allotment Date

Two major healthcare IPOs, the Park Medi World IPO and the Nephrocare Health IPO, are going to open for public subscription tomorrow, i.e., December 10th. Both the mainboard issues come from established players in India's hospital and dialysis markets, leading many investors to compare the Park Medi IPO vs the Nephrocare Health IPO across GMP, price band, financial metrics, risks, and expert recommendations.

Park Medi World IPO: Issue Size, Dates

The Park Medi World IPO is a Rs. 920 crore mainboard IPO, consisting of a fresh issue of Rs. 770 crore and an offer for sale of Rs. 150 crore. The IPO has a price band of Rs. 154 to 162 per share, and the subscription window will remain open from December 10 to December 12. The IPO allotment is scheduled for December 15, and the stock will list on BSE and NSE on December 17, 2025.

Park Mediworld was established in 2011, and it operates one of North India's largest private hospital networks and is the largest private hospital chain in Haryana, offering multi-speciality healthcare services across several northern states.

Nephrocare Health IPO: Issue Size, Dates

The Nephrocare Health IPO is an Rs. 871.05 crore issue, which includes a fresh issue of Rs. 353.40 crore and an offer for sale of Rs. 517.64 crore. The IPO will open from December 10 to December 12, 2025, with allotment expected on December 15 and listing on December 17, 2025.

Nephrocare Health Services is the largest dialysis service provider in India and Asia, commanding over 50% market share in India's organised dialysis market.

GMP Comparison: Park Medi IPO GMP vs Nephrocare Health IPO GMP

As of the latest GMP update on December 9, 2025, the Park Medi IPO GMP stands at Rs. 29, indicating a strong listing sentiment. Based on the upper price band of Rs. 162, the estimated listing price is around Rs. 191, implying potential listing gains of 17.90%.

In contrast, the Nephrocare Health IPO GMP is at Rs. 0 as of today, suggesting a flat listing expectation. However, grey market sentiment may lift up once the IPO opens for subscription tomorrow.

Expert Advice: Should You Apply for These IPOs?

Analysts at Capital Market have assigned a "May Subscribe" rating to the Nephrocare Health IPO, describing it as suitable for investors seeking low-risk, low-return or moderate-risk, moderate-return opportunities. They cite the company's leadership in dialysis services but caution against its heavy reliance on overseas revenue.

The report stated that, "While Nephrocare enjoys industry leadership, a major concern is its dependence on international markets, which contribute nearly 39.96% of revenue in H1 FY26. This exposes the company to risks related to currency movements, geopolitical disruptions, and global healthcare regulatory changes. Any volatility in international markets may directly affect revenue consistency and margins."

For the Park Medi World IPO, multiple brokerages have reviewed the offering, but none have issued a firm recommendation yet.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.